Upon vaccination with Stat3-sufficient CD103+ cDC1s we observed a trend toward increased amounts of tumor antigen (OVA)-specific CD8+ T cells, as indicated by analysis of SIINFEKL/H-2Kb pentamer+ CD8+ T cells, and total Th1 cells within tumors or TdLNs at d 4 post-vaccination, relative to PBS-treated controls, although these increases were not significant statistically (Figure 4). The gene discussed is STAT3; the disease is neoplasm.